ArticleScientific reports2025
Antiproliferative effect of Filopaludina bengalensis fluid inducing apoptosis-necroptosis synergy with immunogenic remodelling in triple-negative breast cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting the tumor microenvironment: a new strategy for natural products in breast cancer therapy.Natural products and bioprospecting · 2026Review
- Looking at the fraction with Annexin V⁺ and propidium iodide⁺: insights into cell death types from preclinical studies in solid and haematological cancers.Apoptosis : an international journal on programmed cell death · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) represents a highly aggressive phenotype of breast carcinoma, distinguished by unique metastatic patterns and poor prognosis driven by its immune microenvironment. Recent advances integrating anticancer agents with personalized immunotherapies are emerging as promising avenues for TNBC management. Freshwater molluscs, though primarily consumed as nutraceuticals and less explored scientifically, hold promising therapeutic potential as immunomodulatory, natural anticancer agents. In the current investigation the anticancer potential of the extrapallial fluid of Filopaludina bengalensis (FBF), a widespread mollusca in south-eastern India, was evaluated against TNBC, exploring its underlying molecular mechanism. Dose-dependent antiproliferative effect in fluid-treated MDA-MB-231 cells ranged from 89.28% at 3.125 µg/ml to 28.4% at 200 µg/ml (p < 0.0001), with an IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.